Choroidal neovascularization describes the growth of new blood vessels that originate from the choroid through a break in the Bruch membrane into the sub–retinal pigment epithelium (sub-RPE) or subretinal space.
The report comprises of key players profiles namely consignment, price, revenue, profit interview records and sources of distribution. It helps clients get a better analysis of their competitors. In addition, it encompasses the regions and countries across the world and depicts the regional outlook, market size, volume, value and price data.
The Choroidal Neovascularization market was valued at xxx million USD with a CAGR xx% from 2015-2019. Subsequently, it will touch xxx million USD in 2020 with a CAGR xx % from 2020 to 2025.
In global market, the following companies are covered:
Pfizer Inc.
F. Hoffmann-La Roche Ltd.
Novartis AG
Regeneron Pharmaceuticals Inc.
Bayer AG
QLT Inc.
Sanwa Kagaku Kenkyusho Co. Ltd.
Promedior Inc.
Valeant Pharmaceuticals International Inc.
Gilead Sciences Inc
Market Segment by Product Type
Intravenous
Intravitreal
Market Segment by Application
Extreme Myopia
Malignant Myopic Degeneration
Age-Related Developments
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The research provides answers to the following key questions:
• What is the estimated growth rate and market share and size of the Choroidal Neovascularization market for the forecast period 2020 - 2025?
• What are the driving forces in the Choroidal Neovascularization market for the forecast period 2020 - 2025?
• Who are the prominent market players and how have they gained a competitive edge over other competitors?
• What are the market trends influencing the progress of the Choroidal Neovascularization industry worldwide?
• What are the major challenges and threats restricting the progress of the industry?
• What opportunities does the market hold for the prominent market players?